Philip T. Lavin

Dr. Lavin is an internationally well-known drug developer and Biostatistician with a long history of supporting clinical trials. He was a member of the Biostatistics faculty at the Harvard School of Public Health and a member of the Department of Surgery at Harvard Medical School where he was affiliated for over 25 years. He co-founded Boston Biostatistics which became Aptiv Solutions before being acquired by ICON plc. Dr. Lavin has authored or co-authored 160 peer-reviewed publications in the medical and statistical literature. Dr. Lavin has been the Lead Biostatistician for 64 FDA approvals to date including 39 PMAs (16 orthopaedic, 7 cardiovascular). Dr. Lavin has continuously worked on various device projects in cardiovascular, orthopaedics, periodontal indications plus In-vitro diagnostics, and imaging. Dr. Lavin received his Ph.D. in Applied Mathematics at Brown University in 1972. He is the only person to be elected a Fellow of the American Statistical Association and the Regulatory Affairs Professional Society reflecting his many pioneering contributions to statistics, regulatory approvals, and medicine. He has been associated and working with the Genpro International team for over 10 years.